La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Sunshine Biopharma Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Sunshine Biopharma ha un patrimonio netto totale di $23.5M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $29.3M e $5.8M.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	n/a
Contanti	US$11.51m
Patrimonio netto	US$23.49m
Totale passività	US$5.81m
Totale attività	US$29.30m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Mar 14

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Jan 29

Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Sep 12

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $25.7M ) di SBFM superano le sue passività a breve termine ( $5.3M ).

Passività a lungo termine: Le attività a breve termine di SBFM ( $25.7M ) superano le sue passività a lungo termine ( $511.6K ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: SBFM è esente da debiti.

Riduzione del debito: SBFM al momento non ha debiti, tuttavia non possiamo fare confronti con 5 anni fa perché non abbiamo dati per quel periodo.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: SBFM ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: SBFM ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 55.2 % ogni anno

Sunshine Biopharma Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Sunshine Biopharma, Inc. announced delayed 10-Q filing

Sunshine Biopharma Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Nasdaq Staff Determines to Delist Sunshine Biopharma's Securities Pursuant to its Discretionary Authority Under Listing Rule 5101

Nasdaq Staff Determines to Delist Sunshine Biopharma's Securities Pursuant to its Discretionary Authority Under Listing Rule 5101

Sunshine Biopharma, Inc. announced delayed 10-Q filing

Sunshine Biopharma Announces Update on Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Recent updates

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Sunshine Biopharma, Inc. announced delayed 10-Q filing

Sunshine Biopharma Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Nasdaq Staff Determines to Delist Sunshine Biopharma's Securities Pursuant to its Discretionary Authority Under Listing Rule 5101

Nasdaq Staff Determines to Delist Sunshine Biopharma's Securities Pursuant to its Discretionary Authority Under Listing Rule 5101

Sunshine Biopharma, Inc. announced delayed 10-Q filing

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Sunshine Biopharma Announces Update on Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

New major risk - Shareholder dilution

New major risk - Share price stability

Sunshine Biopharma, Inc. Announces Executive Changes

Sunshine Biopharma, Inc. Announces Executive Changes

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Third quarter 2023 earnings: EPS exceeds analyst expectations

Sunshine Biopharma, Inc., Annual General Meeting, Dec 07, 2023

Sunshine Biopharma Receives 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Sunshine Biopharma, Inc. announced that it has received CAD 5 million in funding

First quarter 2023 earnings released: US$0.077 loss per share (vs US$0.23 loss in 1Q 2022)

Full year 2022 earnings released: US$1.76 loss per share (vs US$4.76 loss in FY 2021)

Sunshine Biopharma, Inc. (NasdaqCM:SBFM) announces an Equity Buyback for $2 million worth of its shares.

Sunshine Biopharma Receives Non-Compliance Notice From Nasdaq

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$1.59 loss in 3Q 2021)

Sunshine Biopharma, Inc. (NasdaqCM:SBFM) completed the acquisition of Nora Pharma Inc. from Malek Chamoun.

Sunshine Biopharma acquires Nora Pharma for C$30M

We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Second quarter 2022 earnings released: US$0.034 loss per share (vs US$1.20 loss in 2Q 2021)

Sunshine Biopharma reports 1H results

First quarter 2022 earnings released: US$0.23 loss per share (vs US$2.82 loss in 1Q 2021)

Sunshine Biopharma, Inc. Files Patent Application Announces mRNA Molecules

Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs

Sunshine Biopharma, Inc.’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells

Less than half of directors are independent

Sunshine Biopharma Common Stock Deleted from Other OTC

Sunshine Biopharma Mice Study for Covid-19 Treatment Progressing as Planned

Sunshine Biopharma, Inc.’s Adva-27a Destroys Cancer Cells Expressing P-glycoprotein, a Marker Present in Over 50% of All Cancer Types

Sunshine Biopharma, Inc. announced that it has received $0.5 million in funding from RB Capital Partners, Inc.

Sunshine Biopharma Receives Recently Ordered New Batch of Adva-27a and Initiates QA/QC Testing

Sunshine Biopharma, Inc. announced delayed 10-Q filing

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane